AU2008259939B2 - Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies - Google Patents

Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies Download PDF

Info

Publication number
AU2008259939B2
AU2008259939B2 AU2008259939A AU2008259939A AU2008259939B2 AU 2008259939 B2 AU2008259939 B2 AU 2008259939B2 AU 2008259939 A AU2008259939 A AU 2008259939A AU 2008259939 A AU2008259939 A AU 2008259939A AU 2008259939 B2 AU2008259939 B2 AU 2008259939B2
Authority
AU
Australia
Prior art keywords
monoclonal antibody
locus
human
transgenic animal
artificial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2008259939A
Other languages
English (en)
Other versions
AU2008259939A1 (en
Inventor
Ronald Buelow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Open Monoclonal Technology Inc
Original Assignee
Open Monoclonal Technology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40111008&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2008259939(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Open Monoclonal Technology Inc filed Critical Open Monoclonal Technology Inc
Publication of AU2008259939A1 publication Critical patent/AU2008259939A1/en
Application granted granted Critical
Publication of AU2008259939B2 publication Critical patent/AU2008259939B2/en
Assigned to OPEN MONOCLONAL TECHNOLOGY, INC. reassignment OPEN MONOCLONAL TECHNOLOGY, INC. Request to Amend Deed and Register Assignors: OMT, INC.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/873—Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
    • C12N15/877—Techniques for producing new mammalian cloned embryos
    • C12N15/8775—Murine embryos
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0608—Germ cells
    • C12N5/0609—Oocytes, oogonia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Environmental Sciences (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
AU2008259939A 2007-06-01 2008-05-30 Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies Active AU2008259939B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US94161907P 2007-06-01 2007-06-01
US60/914,619 2007-06-01
US4432408P 2008-04-11 2008-04-11
US61/044,324 2008-04-11
PCT/US2008/065419 WO2008151081A1 (en) 2007-06-01 2008-05-30 Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies

Publications (2)

Publication Number Publication Date
AU2008259939A1 AU2008259939A1 (en) 2008-12-11
AU2008259939B2 true AU2008259939B2 (en) 2014-03-13

Family

ID=40111008

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008259939A Active AU2008259939B2 (en) 2007-06-01 2008-05-30 Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies

Country Status (21)

Country Link
US (6) US8703485B2 (enExample)
EP (4) EP2602323B1 (enExample)
JP (6) JP5823690B2 (enExample)
KR (4) KR101703299B1 (enExample)
CN (1) CN101784664B (enExample)
AT (1) ATE522611T1 (enExample)
AU (1) AU2008259939B2 (enExample)
CA (2) CA2688834C (enExample)
CY (1) CY1120383T1 (enExample)
DK (3) DK2336329T3 (enExample)
ES (3) ES2372718T3 (enExample)
HR (1) HRP20180506T1 (enExample)
HU (1) HUE037302T2 (enExample)
IL (2) IL202302A (enExample)
LT (1) LT2602323T (enExample)
NZ (1) NZ581396A (enExample)
PL (3) PL2602323T3 (enExample)
PT (3) PT2336329E (enExample)
SG (2) SG10201509853UA (enExample)
SI (1) SI2602323T1 (enExample)
WO (1) WO2008151081A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12016313B2 (en) 2017-01-19 2024-06-25 Omniab Operations, Inc. Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006008548A2 (en) 2004-07-22 2006-01-26 Erasmus University Medical Centre Rotterdam Binding molecules
EP2602323B1 (en) 2007-06-01 2018-02-28 Open Monoclonal Technology, Inc. Compositions and methods for inhibiting endogenous immunoglobin genes and producing transgenic human idiotype antibodies
CN102177235A (zh) * 2008-09-08 2011-09-07 赛莱克蒂斯公司 切割来自谷氨酰胺合成酶基因的dna靶序列的大范围核酸酶变体及其用途
LT2346994T (lt) 2008-09-30 2022-03-10 Ablexis, Llc Knock-in pelė, skirta chimerinių antikūnų gamybai
CN102625655B (zh) 2008-12-04 2016-07-06 桑格摩生物科学股份有限公司 使用锌指核酸酶在大鼠中进行基因组编辑
CN112690250B (zh) * 2008-12-18 2024-03-08 伊拉兹马斯大学鹿特丹医学中心 表达人源化抗体的非人转基因动物及其用途
GB0905023D0 (en) * 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
EP3028565B1 (en) 2009-07-08 2017-09-27 Kymab Limited Animal models and therapeutic molecules
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
US8754287B2 (en) 2009-12-10 2014-06-17 Regeneron Pharmaceuticals, Inc. Mice that make heavy chain antibodies
SMT201900372T1 (it) 2010-02-08 2019-09-09 Regeneron Pharma Topo con catena leggera comune
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
KR102004106B1 (ko) 2010-03-31 2019-07-25 아블렉시스, 엘엘씨 키메라 항체의 제조를 위한 비-인간 동물의 유전적 조작
NZ605966A (en) * 2010-06-17 2015-04-24 Kymab Ltd Animal models and therapeutic molecules
US10662256B2 (en) 2010-07-26 2020-05-26 Trianni, Inc. Transgenic mammals and methods of use thereof
RU2580017C2 (ru) 2010-07-26 2016-04-10 Трианни, Инк. Трансгенные животные и способы применения
US10793829B2 (en) 2010-07-26 2020-10-06 Trianni, Inc. Transgenic mammals and methods of use thereof
RU2612903C2 (ru) 2010-08-02 2017-03-13 Ридженерон Фармасьютикалз, Инк. Мыши, у которых вырабатываются связывающие белки, содержащие vl-домены
WO2012122484A1 (en) 2011-03-09 2012-09-13 Roberto Polakiewicz Methods and reagents for creating monoclonal antibodies
PT2702160T (pt) * 2011-04-27 2020-07-30 Amyris Inc Métodos para modificação genómica
HUE068728T2 (hu) 2011-08-05 2025-01-28 Regeneron Pharma Humanizált univerzális könnyûláncú egerek
EP2757875B2 (en) 2011-09-19 2023-03-22 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
CA3186126A1 (en) 2011-09-21 2013-03-28 Sangamo Biosciences, Inc. Methods and compositions for regulation of transgene expression
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
PL3216871T3 (pl) 2011-10-17 2022-03-21 Regeneron Pharmaceuticals, Inc. Ograniczony łańcuch ciężki immonoglobuliny pochodzącej od myszy
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
JP6275120B2 (ja) * 2012-04-25 2018-02-07 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 大きい標的化ベクターによるヌクレアーゼ媒介標的化
EP2858487B1 (en) 2012-06-12 2019-10-23 Regeneron Pharmaceuticals, Inc. Humanized non-human animals with restricted immunoglobulin heavy chain loci
CN104540382A (zh) * 2012-06-12 2015-04-22 弗·哈夫曼-拉罗切有限公司 用于产生条件性敲除等位基因的方法和组合物
PT2931030T (pt) * 2012-12-14 2020-08-03 Open Monoclonal Tech Inc Polinucleótidos que codificam anticorpos de roedores com idiótipos humanos e animais que os compreendem
RS57582B1 (sr) 2013-02-20 2018-11-30 Regeneron Pharma Nehumane životinje sa modifikovanim sekvencama imunoglobulinskog teškog lanca
EP2967012B1 (en) 2013-03-14 2020-09-16 Erasmus University Medical Center Rotterdam Transgenic non-human mammal for antibody production
WO2014141192A1 (en) 2013-03-15 2014-09-18 Erasmus University Medical Center Generation of heavy chain-only antibodies
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
EP3456831B1 (en) 2013-04-16 2021-07-14 Regeneron Pharmaceuticals, Inc. Targeted modification of rat genome
WO2014172458A1 (en) * 2013-04-16 2014-10-23 University Of Washington Through Its Center For Commercialization Activating an alternative pathway for homology-directed repair to stimulate targeted gene correction and genome engineering
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
WO2015049517A2 (en) 2013-10-01 2015-04-09 Kymab Limited Animal models and therapeutic molecules
MX388127B (es) 2013-12-11 2025-03-19 Regeneron Pharma Metodos y composiciones para la modificacion dirigida de un genoma.
WO2015143406A2 (en) 2014-03-21 2015-09-24 Regeneron Pharmaceuticals, Inc. Vl antigen binding proteins exhibiting distinct binding characteristics
RU2016141307A (ru) 2014-03-21 2018-04-24 Регенерон Фармасьютикалз, Инк. Отличные от человека животные, которые вырабатывают однодоменные связывающие белки
NZ737666A (en) 2014-04-30 2018-10-26 Hanall Biopharma Co Ltd Antibody binding to fcrn for treating autoimmune diseases
US10336825B2 (en) 2014-04-30 2019-07-02 Hanall Biopharma Co., Ltd. Antibody binding to FcRn for treating autoimmune diseases
GB201407852D0 (en) 2014-05-02 2014-06-18 Iontas Ltd Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules
BR112016028564A2 (pt) 2014-06-06 2018-01-30 Regeneron Pharma método para modificar um locus-alvo em uma célula.
SG10201911411YA (en) 2014-06-26 2020-02-27 Regeneron Pharma Methods and compositions for targeted genetic modifications and methods of use
EP3174902B1 (en) 2014-08-01 2019-04-17 Institut National de la Sante et de la Recherche Medicale (INSERM) An anti-cd45rc antibody for use as drug
CA3176380A1 (en) 2014-11-21 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and compositions for targeted genetic modification using paired guide rnas
BR112017013104A2 (pt) 2014-12-19 2018-05-15 Regeneron Pharma métodos para modificar um locus genômico alvo em uma célula, para intensificar a recombinação homóloga em um locus genômico alvo em uma célula e para produzir uma geração f0 de um animal não humano.
US11111314B2 (en) 2015-03-19 2021-09-07 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
EP4335918A3 (en) * 2015-04-03 2024-04-17 Dana-Farber Cancer Institute, Inc. Composition and methods of genome editing of b-cells
WO2017020291A1 (en) 2015-08-06 2017-02-09 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
FI3334763T3 (fi) 2015-08-11 2024-10-30 Wuxi Biologics Ireland Ltd Uusia pd-l1-vasta-aineita
KR20180038055A (ko) * 2015-08-24 2018-04-13 트리아니, 인코포레이티드 면역글로불린의 강화된 생산
WO2017095939A1 (en) 2015-12-03 2017-06-08 Trianni, Inc. Enhanced immunoglobulin diversity
WO2017136734A1 (en) 2016-02-04 2017-08-10 Trianni, Inc. Enhanced production of immunoglobulins
IL263160B2 (en) 2016-06-03 2024-01-01 Regeneron Pharma Non-human animals expressing exogenous terminal deoxynucleotidyltransferase
UA126384C2 (uk) 2016-09-14 2022-09-28 Тенеобіо, Інк. Антитіло, яке зв'язує cd3
US11111313B2 (en) 2016-09-20 2021-09-07 WuXi Biologics Ireland Limited Anti-PCSK9 antibodies
WO2018065552A1 (en) 2016-10-06 2018-04-12 Innate Pharma Anti-cd39 antibodies
SI3558369T1 (sl) 2016-12-21 2025-06-30 Cephalon Llc Protitelesa, ki se specifično vežejo na človeški il-15, in njihova uporaba
IL267485B2 (en) 2016-12-21 2024-01-01 Teneobio Inc Anti-bcma heavy chain-only antibodies and uses thereof
CN110945026B (zh) 2017-06-20 2024-03-19 特纳奥尼股份有限公司 仅有重链的抗bcma抗体
KR20250007003A (ko) 2017-06-20 2025-01-13 테네오바이오, 인코포레이티드 항-bcma 중쇄-단독 항체
JP2020532991A (ja) 2017-09-07 2020-11-19 オーガスタ ユニバーシティ リサーチ インスティテュート，インコーポレーテッド プログラム細胞死タンパク質１に対する抗体
US20200207867A1 (en) 2017-09-13 2020-07-02 Teneobio, Inc. Heavy chain antibodies binding to ectoenzymes
EP3498293A1 (en) 2017-12-15 2019-06-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Treatment of monogenic diseases with an anti-cd45rc antibody
MX2020006494A (es) 2017-12-22 2020-11-24 Teneobio Inc Anticuerpos de cadena pesada que se unen a cd22.
AU2018395273A1 (en) 2017-12-27 2020-08-13 Teneobio, Inc. CD3-delta/epsilon heterodimer specific antibodies
SMT202500038T1 (it) 2018-03-24 2025-03-12 Regeneron Pharma Topi o ratti geneticamente modificati per la generazione di anticorpi terapeutici contro complessi peptide-mhc, metodi di produzione e loro utilizzo
WO2019240999A1 (en) * 2018-06-13 2019-12-19 Crystal Bioscience Inc. Camelization of a human variable domain by gene conversion
JP7515410B2 (ja) * 2018-06-13 2024-07-12 クリスタル バイオサイエンス インコーポレイテッド 複数のジスルフィド架橋によって安定化され、遺伝子変換によって多様化された長いｃｄｒ－ｈ３ｓで抗体を作製するトランスジェニックニワトリ
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
CN112351997B (zh) 2018-07-20 2023-05-26 坦尼奥第二公司 与cd19结合的重链抗体
CA3108071A1 (en) 2018-08-01 2020-02-06 Cephalon, Inc. Anti-cxcr2 antibodies and uses thereof
EP3626265A1 (en) 2018-09-21 2020-03-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-human cd45rc antibodies and uses thereof
EP3914616A1 (en) 2019-01-23 2021-12-01 Encefa Cd31 competitors and uses thereof
AU2020226445B2 (en) 2019-02-18 2025-05-29 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animals with humanized immunoglobulin locus
CN113710707B (zh) 2019-04-05 2024-05-31 特尼奥生物股份有限公司 结合于psma的重链抗体
CN114630838A (zh) 2019-05-20 2022-06-14 法国国家健康和医学研究院 新的抗cd25抗体
CN119564852A (zh) 2019-06-14 2025-03-07 特尼奥生物股份有限公司 与cd22和cd3结合的多特异性重链抗体
WO2021058795A2 (en) 2019-09-27 2021-04-01 Stark Labs Senescent cell-associated antigen-binding domains, antibodies and chimeric antigen receptors comprising the same, and uses thereof
WO2021113297A1 (en) 2019-12-02 2021-06-10 Regeneron Pharmaceuticals, Inc. Peptide-mhc ii protein constructs and uses thereof
CN115715220A (zh) 2020-04-29 2023-02-24 特尼奥生物股份有限公司 具有经修饰重链恒定区的多特异性重链抗体
AU2021283564B2 (en) 2020-06-02 2025-05-29 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animals with common light chain immunoglobulin locus
EP4211155A1 (en) 2020-09-11 2023-07-19 Regeneron Pharmaceuticals, Inc. Identification and production of antigen-specific antibodies
WO2022106663A1 (en) 2020-11-20 2022-05-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-cd25 antibodies
CN116917318A (zh) 2020-11-20 2023-10-20 法国国家健康和医学研究院 抗cd25抗体
EP4262373A1 (en) 2020-12-16 2023-10-25 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
JP7758739B2 (ja) 2020-12-23 2025-10-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッド アンカー改変型抗体をコードする核酸およびその使用
WO2023147470A2 (en) 2022-01-28 2023-08-03 Georgiamune Inc. Antibodies to programmed cell death protein 1 that are pd-1 agonists
WO2023170207A1 (en) 2022-03-09 2023-09-14 Alderaan Biotechnology Anti-cd160 transmembrane isoform antibodies
KR20250018382A (ko) 2022-05-30 2025-02-05 한올바이오파마주식회사 안정성이 향상된 항-FcRn 항체 또는 이의 항원 결합 단편
WO2024062019A1 (en) 2022-09-21 2024-03-28 Synabs Anti-ccr8 antibodies and uses thereof
WO2025191147A1 (en) 2024-03-14 2025-09-18 Synabs Anti-ccr8 antibodies and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6075181A (en) * 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4977081A (en) 1987-05-04 1990-12-11 Adi Diagnostics, Inc. Stable rabbit-mouse hybridomas and secretion products thereof
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
US5574205A (en) * 1989-07-25 1996-11-12 Cell Genesys Homologous recombination for universal donor cells and chimeric mammalian hosts
US6657103B1 (en) * 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) * 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69133566T2 (de) * 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US6713610B1 (en) * 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US6673986B1 (en) * 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5411881A (en) 1990-07-10 1995-05-02 Nkk Corporation Chicken-specific immunoglobulin G-producing hybridoma
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
JPH06506105A (ja) 1990-08-29 1994-07-14 ファーミング　ビーブイ 哺乳動物細胞における相同性組換え
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
DE4119749A1 (de) 1991-06-15 1992-12-17 Claas Ohg Verfahren zum entholzen von flachs und flachsaufbereitungsmaschine zur durchfuehrung dieses verfahrens
WO1994002602A1 (en) 1992-07-24 1994-02-03 Cell Genesys, Inc. Generation of xenogeneic antibodies
EP0583980A1 (en) 1992-08-20 1994-02-23 Eli Lilly And Company Method for generating monoclonal antibodies from rabbits
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
EP0656946B2 (en) 1992-08-21 2010-03-31 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US5795974A (en) 1993-12-10 1998-08-18 University Of Utah Research Foundation Mycoplasma arthritidis superantigen
US6091001A (en) 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
JP4312259B2 (ja) 1995-04-27 2009-08-12 アムジェン フレモント インク． 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体
AU7326796A (en) 1995-10-30 1997-05-22 Spectral Diagnostics Inc. Stable chicken b-cell line and method of use thereof
US5716081A (en) 1996-03-11 1998-02-10 Automotive Products (Usa), Inc. Spring clip for quick connect coupling
DE69738539T2 (de) * 1996-12-03 2009-03-26 Amgen Fremont Inc. Vollkommen humane Antikörper die EGFR binden
GB9823930D0 (en) 1998-11-03 1998-12-30 Babraham Inst Murine expression of human ig\ locus
EP1141360A4 (en) * 1998-12-31 2002-11-06 David Gladstone Inst Transgenic rodents and rodent cell lines that express HIV receptors.
US6833268B1 (en) * 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
WO2001027279A1 (en) * 1999-10-12 2001-04-19 Cambridge Antibody Technology Human anti-adipocyte monoclonal antibodies and their use
US7262336B2 (en) * 2000-04-24 2007-08-28 Wyeth Transgenic animal
CA2634294A1 (en) * 2000-08-03 2002-02-14 Therapeutic Human Polyclonals, Inc. Production of humanized antibodies in transgenic animals
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DK1354034T3 (da) 2000-11-30 2008-03-25 Medarex Inc Transgene transchromosomale gnavere til fremstilling af humane antistoffer
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
US20040199934A1 (en) 2001-08-20 2004-10-07 Hess John W Transgenic rodents as animal moldels for modulation of b1 bradykinin receptor protein
DK1427828T3 (da) * 2001-09-14 2010-07-19 Cellectis Tilfældig integration af et polynucleotid efter in vivo-linearisering
US7435871B2 (en) 2001-11-30 2008-10-14 Amgen Fremont Inc. Transgenic animals bearing human Igλ light chain genes
WO2003078619A1 (en) 2002-03-15 2003-09-25 Cellectis Hybrid and single chain meganucleases and use thereof
US20030232410A1 (en) * 2002-03-21 2003-12-18 Monika Liljedahl Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
GB0228210D0 (en) 2002-12-03 2003-01-08 Babraham Inst Single chain antibodies
EP1590468A2 (en) 2003-01-28 2005-11-02 Cellectis Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof
US20040158880A1 (en) * 2003-02-05 2004-08-12 Roland Buelow Suppression of endogenous immunoglobulin expression in transgenic non-human animals expressing humanized or human antibodies
GB2398784B (en) 2003-02-26 2005-07-27 Babraham Inst Removal and modification of the immunoglobulin constant region gene cluster of a non-human mammal
NZ544618A (en) * 2003-06-16 2009-02-28 Celltech R & D Inc Antibodies specific for sclerostin and methods for increasing bone mineralization
MXPA06000562A (es) * 2003-07-15 2006-03-30 Therapeutic Human Polyclonals Loci de inmunoglobulina humanizada.
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US20050153392A1 (en) * 2003-08-11 2005-07-14 Roland Buelow Transgenesis with humanized immunoglobulin loci
WO2005038001A2 (en) * 2003-10-14 2005-04-28 Therapeutic Human Polyclonals, Inc. Improved transgenesis by sperm-mediated gene transfer
KR101386690B1 (ko) 2004-03-04 2014-04-22 도쿠리츠교세이호진 고쿠리츠간켄큐센터 래트 배아 줄기 세포
WO2006008548A2 (en) 2004-07-22 2006-01-26 Erasmus University Medical Centre Rotterdam Binding molecules
ES2679282T3 (es) * 2004-10-22 2018-08-23 Revivicor Inc. Porcinos transgénicos que carecen de cadena ligera de inmunoglobulina endógena
JP2008517600A (ja) * 2004-10-22 2008-05-29 セラピューティック ヒューマン ポリクローナルズ， インコーポレイテッド ヒト以外のトランスジェニック動物における内因性免疫グロブリン発現の抑制
EP1854473A1 (en) 2005-03-03 2007-11-14 Takeda Pharmaceutical Company Limited Preventive/therapeutic agent for cancer
WO2006097784A1 (en) 2005-03-15 2006-09-21 Cellectis I-crei meganuclease variants with modified specificity, method of preparation and uses thereof
WO2006097854A1 (en) 2005-03-15 2006-09-21 Cellectis Heterodimeric meganucleases and use thereof
WO2007060495A1 (en) * 2005-10-25 2007-05-31 Cellectis I-crei homing endonuclease variants having novel cleavage specificity and use thereof
US7491866B2 (en) 2005-11-09 2009-02-17 Board Of Regents University Of Texas System Transgenic rats and spermatogonial stem cells
BRPI0706750A2 (pt) 2006-01-25 2011-04-05 Univ Erasmus Medical Ct geração de anticorpos de cadeia pesada em animais transgênicos
EP2505058A1 (en) 2006-03-31 2012-10-03 Medarex, Inc. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
EP2602323B1 (en) * 2007-06-01 2018-02-28 Open Monoclonal Technology, Inc. Compositions and methods for inhibiting endogenous immunoglobin genes and producing transgenic human idiotype antibodies
RS57582B1 (sr) * 2013-02-20 2018-11-30 Regeneron Pharma Nehumane životinje sa modifikovanim sekvencama imunoglobulinskog teškog lanca

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6075181A (en) * 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12016313B2 (en) 2017-01-19 2024-06-25 Omniab Operations, Inc. Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci

Also Published As

Publication number Publication date
US8703485B2 (en) 2014-04-22
HRP20180506T1 (hr) 2018-05-04
EP3382022A1 (en) 2018-10-03
ES2393826T3 (es) 2012-12-28
EP2602323B1 (en) 2018-02-28
DK2336329T3 (da) 2013-01-07
JP2010529042A (ja) 2010-08-26
CN101784664A (zh) 2010-07-21
US20190169270A1 (en) 2019-06-06
US20210253673A1 (en) 2021-08-19
IL202302A0 (en) 2011-08-01
CA2688834A1 (en) 2008-12-11
EP2336329B8 (en) 2012-11-21
US9388233B2 (en) 2016-07-12
IL220209A0 (en) 2012-07-31
KR101661357B1 (ko) 2016-09-29
US20090098134A1 (en) 2009-04-16
PL2152880T3 (pl) 2012-03-30
KR102096731B1 (ko) 2020-04-02
KR101886610B1 (ko) 2018-08-09
PL2336329T3 (pl) 2013-04-30
CA2688834C (en) 2020-01-07
AU2008259939A1 (en) 2008-12-11
SI2602323T1 (en) 2018-05-31
JP2015204840A (ja) 2015-11-19
CA3054224A1 (en) 2008-12-11
DK2152880T3 (da) 2011-11-28
PT2336329E (pt) 2012-12-24
IL220209A (en) 2013-11-28
JP2018000201A (ja) 2018-01-11
SG10201509853UA (en) 2015-12-30
PT2152880E (pt) 2011-12-15
IL202302A (en) 2013-07-31
WO2008151081A8 (en) 2010-02-04
ES2372718T3 (es) 2012-01-25
CY1120383T1 (el) 2019-07-10
CN101784664B (zh) 2013-04-10
US20120090041A1 (en) 2012-04-12
KR20150101475A (ko) 2015-09-03
LT2602323T (lt) 2018-04-10
JP6712254B2 (ja) 2020-06-17
US8907157B2 (en) 2014-12-09
JP6220827B2 (ja) 2017-10-25
HUE037302T2 (hu) 2018-08-28
NZ581396A (en) 2012-07-27
DK2602323T3 (en) 2018-04-16
KR20180090395A (ko) 2018-08-10
SG182144A1 (en) 2012-07-30
ES2664218T3 (es) 2018-04-18
EP2152880A1 (en) 2010-02-17
JP2020125360A (ja) 2020-08-20
ATE522611T1 (de) 2011-09-15
KR20170016518A (ko) 2017-02-13
EP2336329B1 (en) 2012-10-10
JP2022118217A (ja) 2022-08-12
EP2336329A1 (en) 2011-06-22
WO2008151081A1 (en) 2008-12-11
JP5823690B2 (ja) 2015-11-25
US20160311888A1 (en) 2016-10-27
PL2602323T3 (pl) 2018-06-29
PT2602323T (pt) 2018-04-02
JP2014027947A (ja) 2014-02-13
CN102850452A (zh) 2013-01-02
EP2152880B1 (en) 2011-08-31
KR101703299B1 (ko) 2017-02-06
KR20100037027A (ko) 2010-04-08
US20100212035A1 (en) 2010-08-19
US10072069B2 (en) 2018-09-11
HK1135138A1 (en) 2010-05-28
EP2152880A4 (en) 2010-06-16
EP2602323A1 (en) 2013-06-12

Similar Documents

Publication Publication Date Title
US20210253673A1 (en) Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies
JP2010529042A6 (ja) 内在性免疫グロブリン遺伝子を阻害し、そして、トランスジェニック・ヒト・イディオタイプ抗体を製造するための組成物及び方法
HK1261736A1 (en) Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies
HK1186493A (en) Compositions and methods for inhibiting endogenous immunoglobin genes and producing transgenic human idiotype antibodies
HK1186493B (en) Compositions and methods for inhibiting endogenous immunoglobin genes and producing transgenic human idiotype antibodies
HK1135138B (en) Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE PATENTEE TO READ OPEN MONOCLONAL TECHNOLOGY, INC.

HB Alteration of name in register

Owner name: OPEN MONOCLONAL TECHNOLOGY, INC.

Free format text: FORMER NAME(S): OMT, INC.